- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/96 - Two oxygen atoms
Patent holdings for IPC class C07D 239/96
Total number of patents in this class: 138
10-year publication summary
|
16
|
6
|
4
|
8
|
10
|
15
|
11
|
5
|
11
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| IMPACT Therapeutics, Inc. | 36 |
10 |
| Omeros Corporation | 304 |
5 |
| Shandong Cynda Chemical Co., Ltd. | 13 |
4 |
| EA Pharma Co., Ltd. | 93 |
3 |
| Technion Research & Development Foundation Ltd. | 1250 |
3 |
| Edgewise Therapeutics, Inc. | 66 |
3 |
| Inipharm, Inc. | 30 |
3 |
| Impact Therapeutics (Shanghai), Inc | 60 |
3 |
| The Regents of the University of California | 20587 |
2 |
| Glaxosmithkline Intellectual Property Development Limited | 774 |
2 |
| Ajinomoto Co., Inc. | 2277 |
2 |
| Takeda Pharmaceutical Company Limited | 2716 |
2 |
| Consejo Superior de Investigaciones Cientificas | 816 |
2 |
| Emory University | 1703 |
2 |
| Gilead Sciences, Inc. | 2190 |
2 |
| Ideaya Biosciences, Inc. | 147 |
2 |
| Ludwig Institute for Cancer Research Ltd | 193 |
2 |
| Shin Poong Pharmaceutical Co., Ltd. | 39 |
2 |
| Shionogi & Co., Ltd. | 867 |
2 |
| Sutro Biopharma, Inc. | 180 |
2 |
| Other owners | 80 |